Assessment of the benefit of achieving complete versus almost complete skin clearance in psoriasis: a patient’s perspective

References

• Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 Pt 1):401–407.
   PubMed Web of Science ®Google Scholar
• Choi J, Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol. 2003;49(2 Suppl):S57–S61.
   PubMed Web of Science ®Google Scholar
• Mukhtar R, Choi J, Koo JY. Quality-of-life issues in psoriasis. Dermatol Clin. 2004;22(4):389–395.
   PubMed Web of Science ®Google Scholar
• Jung S, Lee SM, Suh D, et al. The association of socioeconomic and clinical characteristics with health-related quality of life in patients with psoriasis: a cross-sectional study. Health Qual Life Outcomes. 2018;16(1):180.
   PubMedGoogle Scholar
• Korman NJ, Zhao Y, Pike J, et al. Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA. Clin Exp Dermatol. 2016;41(5):514–521.
   PubMed Web of Science ®Google Scholar
• Khawaja AR, Bokhari SM, Tariq R, et al. Disease severity, quality of life, and psychiatric morbidity in patients with psoriasis with reference to sociodemographic, lifestyle, and clinical variables: a prospective, cross-sectional study from Lahore, Pakistan. Prim Care Companion CNS Disord. 2015;17(3): doi:https://doi.org/10.4088/PCC.14m01629
   Google Scholar
• Mattei PL, Corey KC, Kimball AB. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28(3):333–337.
   PubMed Web of Science ®Google Scholar
• Nayak PB, Girisha BS, Noronha TM. Correlation between disease severity, family income, and quality of life in psoriasis: a study from south India. Indian Dermatol Online J. 2018;9:165–169.
   PubMedGoogle Scholar
• Murage MJ, Anderson A, Casso D, et al. Treatment patterns, adherence, and persistence among psoriasis patients treated with biologics in a real-world setting, overall and by disease severity. J Dermatolog Treat. 2018;30(2):141–149. doi:https://doi.org/10.1080/09546634.2018.1479725
   Google Scholar
• Murage MJ, Anderson A, Oliveria SA, et al. Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severity. J Med Econ. 2018b;21(8):745–754.
   PubMed Web of Science ®Google Scholar
• Murage MJ, Tongbram V, Feldman SR, et al. Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review. Patient Prefer Adherence. 2018c;12:1483–1503.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Foster SA, Comer BS, et al. Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization. BMC Dermatol. 2018;18(1):4.
   PubMedGoogle Scholar
• Menter A. Psoriasis and psoriatic arthritis treatment. Am J Manag Care. 2016;22(8 Suppl):S225–S37.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Siegel MP, Bagel J, et al. From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76(2):290–298.
   PubMed Web of Science ®Google Scholar
• Gulliver W, Lynde C, Dutz JP, et al. Think beyond the skin: 2014 Canadian expert opinion paper on treating to target in plaque psoriasis. J Cutan Med Surg. 2015;19(1):22–27.
   PubMed Web of Science ®Google Scholar
• Spuls PI, Lecluse LL, Poulsen ML, et al. How good are clinical severity and outcome measures for psoriasis?: Quantitative evaluation in a systematic review. J Invest Dermatol. 2010;130(4):933–943.
   PubMed Web of Science ®Google Scholar
• Pascoe VL, Enamandram M, Corey KC, et al. Using the Physician Global Assessment in a clinical setting to measure and track patient outcomes. JAMA Dermatol. 2015; 151(4):375–381.
   PubMed Web of Science ®Google Scholar
• Anderson P, Benford M, Harris N, et al. Real-world physician and patient behaviour across countries: Disease-Specific Programmes - a means to understand. Curr Med Res Opin. 2008;24(11):3063–3072.
   PubMed Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216.
   PubMed Web of Science ®Google Scholar
• Both H, Essink-Bot ML, Busschbach J, et al. Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol. 2007;127(12):2726–2739.
   PubMed Web of Science ®Google Scholar
• Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353–365.
   PubMed Web of Science ®Google Scholar
• StataCorp. 2015. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP.
   Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Strober B, Papp KA, Lebwohl M, et al. Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol. 2016;75(1):77–82.
   PubMed Web of Science ®Google Scholar
• Fairchild AO, Reed SD, Johnson FR, et al. What is clearance worth? Patients' stated risk tolerance for psoriasis treatments. J Dermatolog Treat. 2017;28(8):709–715.
   PubMed Web of Science ®Google Scholar
• Richards HL, Fortune DG, Weidmann A, et al. Detection of psychological distress in patients with psoriasis: low consensus between dermatologist and patient. Br J Dermatol. 2004;151(6):1227–1233.
   PubMed Web of Science ®Google Scholar
• Moon HS, Mizara A, McBride SR. Psoriasis and psycho-dermatology. Dermatol Ther (Heidelb)). 2013;3(2):117–130.
   PubMedGoogle Scholar
• Nelson PA, Chew-Graham CA, Griffiths CE, IMPACT Team, et al. Recognition of need in health care consultations: a qualitative study of people with psoriasis. Br J Dermatol. 2013;168(2):354–361.
   PubMed Web of Science ®Google Scholar
• Baughman RD, Sobel R. Psoriasis. A measure of severity. Arch Dermatol. 1970;101(4):390–395.
   PubMedGoogle Scholar
• Dawn A, Yosipovitch G. Treating itch in psoriasis. Dermatol Nurs. 2006;18(3):227–233.
   PubMedGoogle Scholar
• Nakamura M, Toyoda M, Morohashi M. Pruritogenic mediators in psoriasis vulgaris: comparative evaluation of itch-associated cutaneous factors. Br J Dermatol. 2003;149(4):718–730.
   PubMed Web of Science ®Google Scholar
• Khoury LR, Danielsen PL, Skiveren J. Body image altered by psoriasis. A study based on individual interviews and a model for body image. J Dermatolog Treat. 2014;25(1):2–7.
   PubMed Web of Science ®Google Scholar
• Nazik H, Nazik S, Gul FC. Body Image, Self-esteem, and Quality of Life in Patients with Psoriasis. Indian Dermatol Online J. 2017;8(5):343–346.
   PubMedGoogle Scholar
• Molina-Leyva A, Jiménez-Moleón JJ, Naranjo-Sintes R, et al. Sexual dysfunction in psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2015;29(4):649–655.
   PubMed Web of Science ®Google Scholar
• Yosipovitch G, Foley P, Ryan C, et al. Ixekizumab Improved Patient-Reported Genital Psoriasis Symptoms and Impact of Symptoms on Sexual Activity vs. Placebo in a Randomized, Double-Blind Study. J Sex Med. 2018; 15(11):1645–1652.
   PubMed Web of Science ®Google Scholar
• Puig L, Thom H, Mollon P, et al. Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2017;31(2):213–220.
   PubMed Web of Science ®Google Scholar
• Takeshita J, Callis Duffin K, Shin DB, et al. Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting. J Am Acad Dermatol. 2014;71(4):633–641.
   PubMed Web of Science ®Google Scholar
• Viswanathan HN, Chau D, Milmont CE, et al. Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis. J Dermatolog Treat. 2015;26(3):235–239.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Bushnell DM, Klekotka PA, et al. Differences in psoriasis signs and symptom severity between patients with clear and almost clear skin in clinical practice. J Dermatolog Treat. 2016;27(3):224–227.
   PubMed Web of Science ®Google Scholar
• Schaefer CP, Cappelleri JC, Cheng R, et al. Health care resource use, productivity, and costs among patients with moderate to severe plaquepsoriasis in the United States. J Am Acad Dermatol. 2015;73(4):585–593.
   PubMed Web of Science ®Google Scholar
• Villacorta R, Teeple A, Lee S, et al. A multinational assessment of work-related productivity loss and indirect costs for patients with psoriasis. Br J Dermatol. 2019. doi:https://doi.org/10.1111/bjd.18798
   Google Scholar
• Reaney M, Mathieu C, Ostenson CG, et al. Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study. Health Qual Life Outcomes. 2013;11(1):217.
   PubMedGoogle Scholar
• European Society for Opinion and Market Research ESOMAR. Available at: http://www.esomar.org. Accessed 28 October 2019.
   Google Scholar
• U.S. Department of Health and Human Services National Institutes of Health HIPAA. Available at: http://privacyruleandresearch.nih.gov/pr_08.asp#8a. Accessed 28 October 2019.
   Google Scholar
• The UK Market Research Society (MRS). Available at: http://www.mrs.org.uk. Accessed 28 October 2019.
   Google Scholar